Cargando…
Absolute Neutrophil Count after the First Chemotherapy Cycle as a Surrogate Marker for Treatment Outcomes in Patients with Neuroblastoma
PURPOSE: We performed this study to determine whether the degree of neutropenia after the first chemotherapy cycle can be used as a surrogate marker of individual susceptibility to chemotherapeutic agents affecting treatment outcome in patients with neuroblastoma. MATERIALS AND METHODS: The study in...
Autores principales: | Lee, Ji Won, Bae, Joon Seol, Kim, Jin Ho, Cho, Hee Won, Ju, Hee Young, Yoo, Keon Hee, Koo, Hong Hoe, Woo, Sook-young, Kim, Seonwoo, Sung, Ki Woong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756108/ https://www.ncbi.nlm.nih.gov/pubmed/33848412 http://dx.doi.org/10.4143/crt.2021.010 |
Ejemplares similares
-
Clinical significance of germline telomere length and associated genetic factors in patients with neuroblastoma
por: Bae, Joon Seol, et al.
Publicado: (2022) -
Excellent treatment outcomes in children younger than 18 months with stage 4 MYCN nonamplified neuroblastoma
por: Kim, Chiwoo, et al.
Publicado: (2018) -
Genome-Wide Association Study for the Identification of Novel Genetic Variants Associated with the Risk of Neuroblastoma in Korean Children
por: Bae, Joon Seol, et al.
Publicado: (2020) -
ARID1B alterations identify aggressive tumors in neuroblastoma
por: Lee, Soo Hyun, et al.
Publicado: (2017) -
Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma
por: Lee, Na Hee, et al.
Publicado: (2016)